Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib as subsequent therapy to an immune checkpoint inhibitor-based therapy in renal cell carcinoma (AT ASIA)
KCT0005866Phase 2Not yet recruiting
- Sponsor
- Ipsen
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Ipsen. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on KCT0005866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005866.